ClinicalTrials.gg
TerminatedNCT02553330Updated Dec 16, 2020Results posted

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

A Phase 2 interventional study of Placebo Cream and Ruxolitinib Phosphate Cream in Alopecia Areata, sponsored by Incyte Corporation. Terminated at 18 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early based on the results of a planned interim analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
24th of 84
90 · median 46
Started
2015
with 3 others
Phase 2
42 of 98
8 open now
Registered
25th of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 24th largest by enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2015, is one of 42 in phase 2, and was the 25th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Hair loss
  • alopecia areata
  • alopecia totalis
  • alopecia universalis
  • JAK inhibitors
  • topical hair growth
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AA
  • Duration and extent of current episode of AA
  • Evidence of active hair loss

Exclusion criteria

Exclusion Criteria:

  • Evidence of diffuse, spontaneous terminal hair regrowth
  • Receipt of treatment known to potentially affect the course of AA within last month
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Ruxolitinib Phosphate Cream

    Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks; Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks.

    Drug: Ruxolitinib Phosphate Cream

  • Placebo comparator
    Placebo Cream

    Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.

    Drug: Placebo Cream · Drug: Ruxolitinib Phosphate Cream

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).

    Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.

    Time frame: Up to Week 24

  2. Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented)

    Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.

    Time frame: Week 24

Secondary outcomes

  1. Part A : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair.

    Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.

    Time frame: Up to Week 24

  2. Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).

    Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.

    Time frame: Week 24

  3. Part A and B : Percentage of Participants Achieving a SALT90 Response in Terminal Hair.

    Number of participants achieving 90% or greater improvement in their SALT score (SALT90) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.

    Time frame: Weeks 4, 8, 12, 18, and 24.

  4. Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3

    Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, \<25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).

    Time frame: Baseline to Week 24

  5. Part B : Percentage of Participants Achieving a SALT50 in Terminal Hair (Pigmented and Nonpigmented).

    Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes

    Time frame: Weeks 4, 8, 12, and 18.

  6. Part B: Mean Change From Baseline in SALT Score

    Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).

    Time frame: Weeks 4, 8, 12, 18, and 24.

  7. Part A and B : Number of Treatment-emergent Adverse Events

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment

    Time frame: Up to 100 weeks

07

Results

Posted Dec 16, 2020

Participant flow

This study was conducted at 17 study centers in the United States.

Participant flow — Overall Study
MilestonePart A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib Cream
Started123939
Completed702
Not completed53937
Withdrew: Study terminated by sponsor21312
Withdrew: Withdrawal by subject31921
Withdrew: Other010
Withdrew: Non compliance to study treatment010
Withdrew: Adverse event010
Withdrew: Lost to follow-up044

Outcome measures

PrimaryPart A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).

Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).
ParticipantsPart A: Ruxolitinib Cream
Week 40
Week 80
Week 123
Week 184
Week 246
PrimaryPart B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented)

Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented)
ParticipantsPart B : Placebo CreamPart B: Ruxolitinib Cream
Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented)55
SecondaryPart A : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair.

Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Part A : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair.
ParticipantsPart A: Ruxolitinib Cream
Week 40
Week 80
Week 122
Week 183
Week 244
SecondaryPart B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).

Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).
ParticipantsPart B : Placebo CreamPart B : Ruxolitinib Cream
Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).24
SecondaryPart A and B : Percentage of Participants Achieving a SALT90 Response in Terminal Hair.

Number of participants achieving 90% or greater improvement in their SALT score (SALT90) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.

Time frame:
Weeks 4, 8, 12, 18, and 24.
Reported as:
Count of participants · Participants
Part A and B : Percentage of Participants Achieving a SALT90 Response in Terminal Hair.
ParticipantsPart A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib Cream
Week4000
Week 8000
Week 12001
Week 18102
Week 24202
SecondaryPart B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3

Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, \<25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3
ParticipantsPart B : Placebo CreamPart B : Ruxolitinib Cream
Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 352
SecondaryPart B : Percentage of Participants Achieving a SALT50 in Terminal Hair (Pigmented and Nonpigmented).

Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes

Time frame:
Weeks 4, 8, 12, and 18.
Reported as:
Count of participants · Participants
Part B : Percentage of Participants Achieving a SALT50 in Terminal Hair (Pigmented and Nonpigmented).
ParticipantsPart B : Placebo CreamPart B : Ruxolitinib Cream
Week 400
Week 802
Week 1213
Week 1845
SecondaryPart B: Mean Change From Baseline in SALT Score

Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).

Time frame:
Weeks 4, 8, 12, 18, and 24.
Reported as:
Least squares mean · Units on a Scale
Part B: Mean Change From Baseline in SALT Score
Units on a ScalePart B : Placebo CreamPart B : Ruxolitinib Cream
Change from Baseline to Week 41.02 ± 1.5770.13 ± 1.534
Change from Baseline to Week 82.13 ± 2.233-1.11 ± 2.160
Change from Baseline to Week 121.23 ± 2.956-2.55 ± 2.873
Change from Baseline to Week 18-0.01 ± 3.550-4.16 ± 3.461
Change from Baseline to Week 24-1.68 ± 3.886-3.92 ± 3.794
SecondaryPart A and B : Number of Treatment-emergent Adverse Events

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment

Time frame:
Up to 100 weeks
Reported as:
Count of participants · Participants
Part A and B : Number of Treatment-emergent Adverse Events
ParticipantsPart A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib Cream
Treatment Period92823
Extension Period72322

Adverse events

Collected over Up to 100 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Cream0/38 (0%)0/38 (0%)14/38 (36.8%)
Ruxolitinib Cream0/83 (0%)4/83 (4.8%)31/83 (37.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo CreamRuxolitinib Cream
DiverticulitisInfections and infestations0/381/83
Generalised anxiety disorderPsychiatric disorders0/381/83
Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/381/83
Lentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/381/83
Non-cardiac chest painGeneral disorders0/381/83
SepsisInfections and infestations0/381/83
Most frequent other events
Most frequent other events
EventPlacebo CreamRuxolitinib Cream
NasopharyngitisInfections and infestations6/3813/83
PruritusSkin and subcutaneous tissue disorders3/3810/83
SinusitisInfections and infestations1/387/83
Skin exfoliationSkin and subcutaneous tissue disorders3/383/83
Urinary tract infectionInfections and infestations0/385/83
BronchitisInfections and infestations2/382/83

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib CreamTotal
Mean47.6 ± 13.1744.3 ± 15.9242.4 ± 14.6943.4 ± 15.25
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib CreamTotal
Female9242760
Male3151230
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib CreamTotal
White or Caucasian11332973
Black or African American0549
Asian1102
Other0055
Unknown0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Ruxolitinib CreamPart B : Placebo CreamPart B : Ruxolitinib CreamTotal
Hispanic or Latino1359
Not Hispanic or Latino11363380
Not Reported0011
08

Study locations

18 sites
  • Birmingham, Alabama, United States
  • Hot Springs, Arkansas, United States
  • New Haven, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Miami, Florida, United States
  • Beverly, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Clinton Township, Michigan, United States
  • Fort Gratiot, Michigan, United States
  • Fridley, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Portland, Oregon, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Katy, Texas, United States
  • Norfolk, Virginia, United States
09

References and documents

Publications

  • Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024. No abstract available. PubMed 28619556 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Oct 2017, 22 months.

Results were first posted in Dec 2020, 3 years 2 months after primary completion. A results delay was requested in Oct 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2015
First posted
Sep 17, 2015
StartActual
Nov 18, 2015
Primary completionActual
Oct 3, 2017
CompletionActual
Oct 3, 2017
Results delay requested
Oct 9, 2018
Results first posted
Dec 16, 2020
Last update
Dec 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02553330
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 17, 2015
Start date
Nov 18, 2015
Primary completion
Oct 3, 2017
Completion
Oct 3, 2017
Results posted
Dec 16, 2020
Last update
Dec 16, 2020

Study contacts

Kathleen Butler, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion